By Yvonne Saenger, MD
Melanoma care has fortunately undergone a whirlwind of changes over the past several years. Novel immunotherapies are perhaps the most exciting recent development in cancer care because patients can enjoy long-term benefit from these treatments, meaning that they are possibly “cured.”
By Silas Inman
The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy and harbor a 17p deletion.
Primary human papillomavirus (HPV) testing every 3 years seems to be a better screening alternative to Papanicolaou (Pap) testing every 3 years or concurrent HPV and Pap testing every 5 years, according to a study published online July 18 in the Journal of the National Cancer Institute.
Repeat colonoscopies within 10 years are of little benefit to patients who had no polyps found on adequate examination; however, repeat colonoscopies do benefit patients when the baseline examination was compromised, according to research published in the August issue of Gastroenterology.
Adolescent girls undergoing treatment for cancer are at high risk for heavy menstrual bleeding, and gynecologic care is advised for careful management of this problem, according to a Committee Opinion published in the August issue of Obstetrics & Gynecology.
Lymphoma treatment has damaging effects on spermatogenesis but, in most patients, sperm production recovers within 2 years post-treatment, according to a study published online July 17 in Fertility and Sterility.
Most Americans focus on provider quality related to doctor-patient interactions rather than effectiveness of care when defining provider quality, according to a report published by the Associated Press-NORC Center for Public Affairs Research.
Implementation of an enhanced recovery after surgery colorectal program is feasible in a community hospital setting and significantly improves outcomes, according to a study published online July 23 in JAMA Surgery.
By Anita T. Shaffer
A growing understanding of the biological pathways at work in the development of oral mucositis in patients treated with cytotoxic cancer therapies has helped spur interest in steering symptom management away from “institutional folklore” rinses and anecdotal approaches toward evidence-based strategies
United States oncology fellows may underestimate the workload they will experience once they enter practice, according to research published online July 21 in the Journal of Clinical Oncology.
By Jackie Syrop
During the first open enrollment period under the Affordable Care Act, more than 10 million Americans gained health insurance coverage.
By Andrew J. Roth
A phase III trial analyzing sorafenib for the treatment of patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival.
An "unacceptably low" number of girls and boys are getting the human papillomavirus vaccine, which protects against cervical, anal, and other cancers, US health officials said Thursday.
A questionnaire improves discussion of psychosocial problems during genetic counseling sessions for cancer, according to research published online July 21 in the Journal of Clinical Oncology.
By Anna Azvolinsky, PhD
One-third (30%) of chemotherapy-naïve non–small cell lung cancer (NSCLC) patients treated with nivolumab, an anti-PD-1 immune checkpoint antibody, responded to treatment in a phase I study.
By Wayne Kuznar
In the first pivotal phase III study of a Janus-associated kinase (JAK) inhibitor for the treatment of polycythemia vera (PV), ruxolitinib (Jakafi) was superior to best available therapy (BAT) in maintaining control of hematocrit without the need for phlebotomy and in reducing spleen size in patients with an inadequate response to or intolerance of hydroxyurea.
By Raoul S. Concepcion, MD
I am sure that those of you who attended the AUA meeting in Orlando were struck by the number of presentations on the use of biomarkers and their role in better risk stratification and management of the urologic oncology patient.
By Tony Berberabe, MPH
Keeping your practice financially solvent is difficult because of the uncertainty of regulatory and reform mandates, electronic health records requirements, and diminishing reimbursements. But a type of care delivery, called concierge care, is making some inroads in the primary care arena—and may hold some usefulness in oncology practice.
By Silas Inman
The FDA has approved idelalisib in combination with rituximab for patients with high-risk relapsed or refractory CLL and as a single-agent for two types of iNHL.
By Silas Inman
Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly extended improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab